| abstract |
DGAT-1 inhibitor compounds of formula (I), pharmaceutically acceptable salts and prodrugs thereof, together with pharmaceutical compositions, processes for their manufacture and their use in the treatment of, for example, obesity where the ring A, X, ring B, Y1, Y2 n, ring C, L, p, Ra1 and Ra2, Z are as defined in the preceding documentation |